|Example 1. MAMS platform AD|
Figure 2 illustrates the graphical reporting of recruitment and follow-up periods for each treatment group including new arms that were added during the STAMPEDE trial. Corresponding comparator groups (controls) for treatment comparisons are indicated.
Example 2. Phase 2 Bayesian biomarker-targeted AD with RAR
“A total of 341 patients were enrolled in the BATTLE study between November 30, 2006, and October 28, 2009, with equally random assignments for the first 97 patients and adaptive randomization for the remaining 158.”